1-2 of 2
David Wrench
Close
Sort by
Journal Articles

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study

Clinical Trials & Observations
Ann Tivey, Rohan Shotton, Toby A. Eyre, David Lewis, Louise Stanton, Rebecca Allchin, Harriet Walter, Fiona Miall, Rui Zhao, Anna Santarsieri, Rory McCulloch, Mark Bishton, Amy Beech, Victoria Willimott, Nicole Fowler, Claudia Bedford, Jack Goddard, Sam Protheroe, Angharad Everden, David Tucker, Josh Wright, Vasavi Dukka, Miriam Reeve, Shankara Paneesha, Mahesh Prahladan, Andrew Hodson, Iman Qureshi, Manasvi Koppana, Mary Owen, Kushani Ediriwickrema, Helen Marr, Jamie Wilson, Jonathan Lambert, David Wrench, Claire Burney, Chloe Knott, Georgina Talbot, Adam Gibb, Angela Lord, Barry Jackson, Simon Stern, Taylor Sutton, Amy Webb, Marketa Wilson, Nicky Thomas, Jane Norman, Elizabeth Davies, Lisa Lowry, Jamie Maddox, Neil Phillips, Nicola Crosbie, Marcin Flont, Emma Nga, Andres Virchis, Raisa Guerrero Camacho, Wunna Swe, Arvind Pillai, Clare Rees, James Bailey, Steve Jones, Susan Smith, Faye Sharpley, Catherine Hildyard, Sajir Mohamedbhai, Toby Nicholson, Simon Moule, Anshuman Chaturvedi, Kim Linton
Journal: Blood Advances
Blood Adv (2024) 8 (5): 1209–1219.
https://doi.org/10.1182/bloodadvances.2023011152
Published: 2024
Includes: Supplemental data
Journal Articles

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Clinical Trials & Observations
Michael Northend, William Wilson, Wendy Osborne, Christopher P. Fox, Andrew J. Davies, Dima El-Sharkawi, Elizabeth H. Phillips, Hau Wui Sim, Shalal Sadullah, Nimish Shah, Ying Ying Peng, Iman Qureshi, Juanah Addada, Rocio Figueroa Mora, Neil Phillips, Andrea Kuhnl, Elizabeth Davies, David Wrench, Pamela McKay, Indrani Karpha, Anna Cowley, Richard Karim, Sarah Challenor, Vikram Singh, Cathy Burton, Rebecca Auer, Chris Williams, Joel Cunningham, Angus Broom, Anita Arasaretnam, Claire Roddie, Tobias Menne, William Townsend
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2920–2926.
https://doi.org/10.1182/bloodadvances.2021005953
Published: 2022
Includes: Supplemental data